Nafarelin

Mechanism

The only GnRH agonist available as a nasal spray. Like other GnRH agonists, it suppresses sex hormone production by overwhelming the pituitary gland's GnRH receptors. Used to treat endometriosis and central precocious puberty (early puberty in children). The nasal spray makes it easier to use than injections, though it requires twice-daily dosing.

Effects

**Endocrine — HPG Axis (Tier 1 — Human Clinical):** Nafarelin is a GnRH agonist approximately 200x more potent than endogenous GnRH. Administered intranasally, it follows the standard GnRH agonist pharmacology: initial stimulation (flare) followed by receptor downregulation and gonadal suppression. Unique among GnRH agonists for its nasal spray delivery, avoiding injections entirely. **Reproductive — Female (Tier 1 — Human Clinical):** Achieves medical menopause within 4 weeks of treatment. Effective for endometriosis pain reduction and disease regression. Suppresses ovarian function for IVF pituitary downregulation protocols. **Reproductive — Pediatric (Tier 1 — Human Clinical):** Approved for central precocious puberty. Halts pubertal progression and normalizes growth velocity. The nasal spray formulation is particularly practical for children, avoiding painful depot injections. **Nasal Mucosa (Tier 1 — Clinical Observation):** Nasal irritation, rhinitis, and epistaxis reported in 5–10% of patients. Absorption is affected by nasal congestion, rhinitis, and concurrent nasal decongestant use, leading to variable drug levels.

Practitioner Guide

**APPROVED INDICATIONS:** • Endometriosis. • Central precocious puberty. • IVF (pituitary downregulation — off-label in some regions). **DOSING:** • Endometriosis: 200 mcg (one spray) into one nostril each morning and one spray into the other nostril each evening (400 mcg/day total). If amenorrhea does not occur within 2 months, dose may be increased to 800 mcg/day (two sprays BID). • Central precocious puberty: 1600 mcg/day (two sprays into each nostril, morning and evening = 800 mcg BID). May increase to 1800 mcg/day. • Treatment duration for endometriosis: 6 months maximum without add-back therapy. **CLINICAL PEARLS:** • Nasal administration advantage: No injections, no depot site reactions. Practical for children (precocious puberty) and patients who are needle-averse. • Nasal administration disadvantage: Variable absorption. Upper respiratory infections, allergic rhinitis, and nasal decongestant use can significantly alter drug levels. Instruct patients NOT to use nasal decongestants within 30 minutes of nafarelin. • Sneezing within 30 seconds of administration can expel the dose — instruct patients to tilt head slightly forward and avoid sneezing. • Flare management: Same principles as other GnRH agonists. Anti-androgen cover is rarely needed in the female endometriosis/IVF context but may be required for off-label male use. • Add-back therapy: Same as leuprolide/goserelin — norethindrone acetate 5 mg daily for treatment beyond 6 months. • Bone density monitoring: Same DEXA protocol as other GnRH agonists. • Storage: Nasal spray should be stored upright at room temperature. Protect from light.

Evidence

• A study on the efficacy and safety of long-term adjusted low-dose gonadotropin-releasing hormone agonist therapy for uterine fibroids and adenomyosis.

  Kashiwabara S et al. (2024) — Journal of Obstetrics and Gynaecology Research — PMID: 39462178

  Adjusted low-dose nafarelin acetate used for a median of 28 months in patients with fibroids and/or adenomyosis stopped menstruation in all patients, raised hemoglobin from roughly 8.6-8.8 g/dL to 13.2-13.3 g/dL by 12 months, prevented lesion growth, and showed relatively modest bone-density decline compared with prior long-term GnRH agonist experience.

  moderate

Research Summary

**Tier 1 (Human Clinical Evidence):** • Endometriosis: RCTs confirm significant pain reduction comparable to danazol and other GnRH agonists. The intranasal route provides equivalent efficacy to injectable GnRH agonists. • Central precocious puberty: Well-established efficacy in halting pubertal progression. The convenience of nasal spray is a significant advantage for pediatric compliance. • IVF: Used successfully in pituitary downregulation protocols, though injectable formulations (leuprolide, goserelin) are more commonly used in most fertility centers. **Tier 2 (Strong Preclinical + Mechanistic):** • 200-fold greater potency than native GnRH at the GnRH receptor. Modified at position 6 (D-Nal substitution) for enzymatic resistance and enhanced receptor affinity. • Nasal absorption pharmacokinetics characterized — peak levels at 10–40 minutes, bioavailability approximately 2–3% (compensated by high intranasal doses). **Tier 3 (Emerging / Theoretical):** • The nasal delivery platform could theoretically deliver other peptides, though nafarelin remains one of the few peptides successfully administered this way at therapeutic levels.